BeCool Pharmaceutics is an Alaska-based small molecule drug development company, focused on creating therapeutics to modulate metabolism and body temperature by mimicking hibernation. It has the potential to improve outcomes for babies suffering from limited oxygen and blood to the brain; as well as possibly a medical condition known as hypoxic-ischemic encephalopathy (HIE).The therapeutic can help with the same problem for individuals who have suffered cardiac arrest or stroke; and it can reduce painful post-operative shivering. Professor Drew, founder and CEO of BeCool, is a world expert in hibernation and neurocritical care and leads an NIH-funded UAF program focused on discovery and translation of druggable targets in hibernation.